Neuroleptic and benzodiazepine use in long-term care in urban and rural Alberta: Characteristics and results of an education intervention to ensure appropriate use

International Psychogeriatrics

Volumn 17, Issue 4, 2005, Pages 631-652

  Hagen, Brad F ^a   Armstrong Esther, Chris ^a   Quail, Paddy ^b   Williams, Robert J ^a   Norton, Peter ^b   Le Navenec, Carole Lynn ^c   Ikuta, Roland ^d   Osis, Maureen ^c   Congdon, Val ^e   Zieb, Roxane ^e  

^a UNIVERSITY OF LETHBRIDGE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Senior's Health   (Canada)

^e CALGARY HEALTH REGION   (Canada)

Author keywords

Aged; Antipsychotic agents; Benzodiazepines; Continuing medical education; Nursing homes

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CLONAZEPAM; DIAZEPAM; HALOPERIDOL; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TEMAZEPAM; TRAZODONE;

AGED; ARTICLE; CANADA; CLINICAL EDUCATION; CONTROLLED STUDY; DEMENTIA; DEMOGRAPHY; DRUG INDICATION; DRUG USE; FAMILY; FEMALE; HEALTH CARE FACILITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; NURSING STAFF; PARKINSON DISEASE; PHARMACIST; PHARMACY; PHYSICIAN; PRESCRIPTION; RESIDENT; RURAL AREA; TIME SERIES ANALYSIS; URBAN AREA;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CANADA; CATCHMENT AREA (HEALTH); DRUG UTILIZATION; FAMILY HEALTH; FEMALE; HEALTH EDUCATION; HEALTH PERSONNEL; HUMANS; MALE; PRESCRIPTIONS, DRUG; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RURAL POPULATION; TEACHING; URBAN POPULATION;

EID: 28744432976     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610205002188     Document Type: Article

References (52)

1. Avorn, J., Dreyer, P., Connelly, K. and Soumerae, S. B. (1989). Use of psychoactive medication and the quality of care in rest homes: findings and policy implications of a statewide study. New England Journal of Medicine, 320, 227-232.
2. Avorn, J. et al. (1992). A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. New England Journal of Medicine, 327, 168-173.
3. Avorn, J. et al. (1995). Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. American Journal of Medicine, 99, 48-54.
4. Bridges-Parlet, S., Knopman, D. and Steffes, S. (1997). Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment controlled pilot study. Journal of Geriatric Psychiatry and Neurology, 10, 119-126.
5. Bronskill, S. E. et al. (2004). Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. Journal of the American Geriatrics Society, 52, 749-755.
6. Buck, J. A. (1988). Psychotropic drug practice in nursing homes. Journal of the American Geriatrics Society, 36, 409-418.
7. Caligiuri, M. P., Rockwell, E. and Jeste, D. V. (1998). Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication. American Journal of Geriatric Psychiatry, 6, 75-82.
8. Cohen-Mansfield, J., Lipson, S., Werner, P., Billig, N., Taylor, L. and Woosley, R. (1999). Withdrawal of haloperidol, thioridazine and lorazepam in the nursing home: a controlled, double-blind study. Archives of Internal Medicine, 159, 1733-1740.
9. Conn, D. K., Ferguson, I., Mandelman, K. and Ward, C. (1999). Psychotropic drug utilization in long-term care facilities for the elderly in Ontario, Canada. International Psychogeriatrics, 11, 223-233.
10. Dewa, C. S. and Goering, P. (2001). Lessons learned from trends in psychotropic drug expenditures in a Canadian province. Psychiatric Services, 52, 1245-1247.
11. Earthy, A., Collins, J., Wong, S. and Myckatyn, M. (2000). Ensuring the appropriate use of neuroleptics. Canadian Nursing Home, 11, 5-10.
12. Frenchman, I. B. and Prince, T. (1997). Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. International Psychogeriatrics, 9, 431-435.
13. Goode, E. Leading drugs for psychosis come under new scrutiny. (2003, May 20). The New York Times, p. A1.
14. Gurvich, T. and Cunningham, J. A. (2000). Appropriate use of psychotropic drugs in nursing homes. American Family Physician, 61, 1437-1446.
15. Hagen, B., Armstrong-Esther, C., Ikuta, R., Williams, R. J., Le Navenac, C. L. and Aho, M. (2005). Antipsychotic drug use in Canadian long-term care facilities: prevalence and patterns following resident relocation. International Psychogeriatrics, 17, 179-193.
16. Health Canada (2002). Important Drug Safety Information, October 11, 2002: Risperdal® (risperidone) and Cerebrovascular Adverse Events in Placebo-controlled Trials. Retrieved June 28, 2005, from http://www.hc-sc.gc.ca/ hpfb-dgpsa/tpd-dpt/risperda/1-e.html
17. Health Canada (2004). Important Drug Safety Information, March 11, 2004: Zyprexa® (olanzapine) and Cerebrovascular Adverse Events in Placebo-controlled Trials. Retrieved June 28, 2005, from http://www.hc-sc.gc.ca/ hpfb-dgpsa/tpd-dpt/zyprexahpce.html
18. Hughes, C., Lapane, K., Mor, V., Ikegami, N., Jonsson, P. V. and Ljunggren, G. (2000). The impact of legislation on psychotropic drug use in nursing homes: a cross-national perspective. Journal of the American Geriatrics Society, 48, 931-937.
19. Jeste, D. V., Lacro, J. P., Bailey, A., Rockwell, E., Harris, M. J. and Caligiuri, M. P. (1999a). Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Journal of the American Geriatrics Society, 47, 716-719.
20. Jeste, D. V., Lacro, J. P., Palmer, B., Rockwell, E., Harris, J. and Caligiuri, M. P. (1999b). Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. American Journal of Psychiatry, 156, 309-311.
21. Jeste, D. V., Rockwell, E., Harris, M. J., Lohr, J. B. and Lacro, J. (1999c). Conventional vs. newer antipsychotics in elderly patients. American Journal of Geriatric Psychiatry, 7, 70-76.
22. Kleinman, F. L., Ciesla, G., Rupnow, M. F. and Brodaty, H. (2004). The effect of risperidone on nursing burden associated with caring for patients with dementia. Journal of the American Geriatrics Society, 52, 1449-1455.
23. Lanctot, K. L. et al. (1998). Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. Journal of Clinical Psychiatry, 59, 550-561.
24. Lantz, M. S., Giambanco, V. and Buchalter, E. N. (1996). A ten-year review of the effect of OBRA-87 on psychotropic prescribing practices in an academic nursing home. Psychiatric Services, 47, 951-955.
25. Lavretsky, H. and Sultzer, D. (1998). A structured trial of risperidone for the treatment of agitation in dementia. American Journal of Geriatric Psychiatry, 6, 127-135.
26. Lee, P. E., Gill, S. S., Freedman, M., Bronskill, S. E., Hillmer, M. P. and Rochon, P. A. (2004). Atypical antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia: systematic review. British Medical Journal, 329 (74-57), 75-79.
27. Leipzig, R. M., Cumming, R. G. and Tinetti, M. E. (1999). Drugs and falls in older people: a systematic review and meta-analysis. Journal of the American Geriatrics Society, 47, 30-39.
28. Llorente, M. D., Olsen, E. J., Leyva, O., Silverman, M. A., Lewis, J. E. and Rivero, J. (1998). Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations. Journal of the American Geriatrics Society, 46, 198-201.
29. Martin, H., Slyk, M. P., Deymann, S. and Cornacchione, M. J. (2003). Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. Journal of the American Medical Directors' Association, 4, 183-188.
30. McShane, R., Keene, J., Gedling, K., Fairburn, C., Jacoby, R. J. and Hope, T. (1997). Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. British Medical Journal, 314, 266-270.
31. Meador, K. G., Taylor, J. A., Thapa, P. B., Fought, R. L. and Ray, W. A. (1997). Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education. Journal of the American Geriatrics Society, 45, 207-210.
32. Melkerson, K. and Dahl, M. L. (2004). Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs, 64, 701-723.
33. OBRA ((1987)). Omnibus Budget Reconciliation Act (OBRA): subtitle C, nursing home reform: PL100-203. Washington, D.C.: National Coalition for Nursing Home Reform.
34. Patterson, C. J. et al. (1999). The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Canadian Medical Association Journal, 160, S1-15.
35. Pierfitte, C. et al. (2001). Benzodiazepines and hip fractures in elderly people: case-control study. BMJ, 322, 704-708.
36. Pimlott, N. J. G. et al. (2003). Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. Canadian Medical Association Journal, 168, 835-839.
37. Ray, W. A., Griffin, M. R., Schaffner, W., Baugh, D. K. and Melton, L. J. (1987) Psychotropic drug use and the risk of hip fracture. New England Journal of Medicine, 316, 363-369.
38. Ray, W. A., Thapa, P. B. and Gideon, P. (2000). Benzodiazepines and the risk of falls in nursing home residents. Journal of the American Geriatrics Society, 48, 682-685.
39. Risse, S. C., Cubberley, L., Lampe, T. H., Zemmers, R. and Raskind, M. A. (1988). Acute effects of neuroleptic withdrawal in elderly dementia patients. Journal of Geriatric Drug Therapy, 2, 65-77.
40. Ruth, S., Straand, J. and Nygaard, H. A. (2001). Psychotropic drug use in nursing homes - diagnostic indications and variations between institutions. European Journal of Clinical Pharmacology, 57, 523-528.
41. Schjott, J., Opedal., K. and Rutledal, U. E. (1999). A survey of hypnotic use in geriatric institutions in Sogn og Fjordane, Norway. Aging: Clinical and Experimental Research, 11, 50-55.
42. Schneider, L. S., Pollock, V. E. and Lyness, S. A. (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society, 38, 553-563.
43. Semla, T. P., Palla, K., Poddig, B. and Brauner, D. J. (1994). Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. Journal of the American Geriatrics Society, 42, 648-652.
44. Snowden, M. and Roy-Byrne, P. (1998). Mental illness and nursing home reform: OBRA-87 ten years later. Psychiatric Services, 49, 229-233.
45. Sorenson, L., Foldspang, A., Gulmann, N. C. and Munk-Jorgensen, P. (2001). Determinants for the use of psychotropics among nursing home residents. International Journal of Geriatric Psychiatry, 16, 147-154.
46. Svarstad, B. L. and Mount, J. K. (1991). Nursing home resources and tranquilizer use among the institutionalized elderly. Journal of the American Geriatrics Society, 39, 869-875.
47. Svarstad, B. L. and Mount, J. K. (2001). Chronic benzodiazepine use in nursing homes: effects of federal guidelines, resident mix, and nurse staffing. Journal of the American Geriatrics Society, 49, 1673-1678.
48. Wagner, A. K. et al. (2004). Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Archives of Internal Medicine, 164, 1567-1572.
49. Wilson, R. R. (2003). Applying Contemporary Statistical Techniques. San Diego, CA: Academic Press.
50. Woerner, M. A., Alvir, J. M., Saltz, B. L., Lieberman, J. A. and Kane, J. M. (1998). Prospective study of tardive dyskinesia in the elderly: rates and risk factors. American Journal of Psychiatry, 155, 1521-1528.
51. Yeo, T. T. et al. (1994). Educational visiting and hypnosedative prescribing in general practice. Family Practice, 11, 57-61.
52. Zwar, N. A., Wolk, J., Gordon, J. J. and Sanson-Fisher, R. W. (2000). Benzodiazepine prescribing by GP registrars: a trial of educational outreach. Australian Family Physician, 29, 1104-1107.